AbCellera Biologics Inc. - Common Shares (NQ:ABCL)

12.63 +0.08 (+0.68%)

Official Closing Price Updated: 4:15 PM EDT, Oct 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AbCellera Biologics Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

AbCellera to Present at Upcoming Investor Conferences in September

August 29, 2024

From AbCellera Biologics Inc.

Via Business Wire

Our AI-Focused Drug Discovery Stocks Portfolio Was Up Almost 7% Last Week ↗

August 27, 2024

The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030.

Via Talk Markets

This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗

August 20, 2024

Via Benzinga

AI-Focused Drug Discovery Stocks Portfolio Hit Hard: Down 14% MTD ↗

August 14, 2024

The AI-powered drug discovery process is expected to grow by a 30% CAGR between now and 2030 which should result in approximately 50 novel therapies and generate annual sales in excess of $50 billion...

Via Talk Markets

AbCellera Biologics (ABCL) Q2 2024 Earnings Call Transcript ↗

August 07, 2024

ABCL earnings call for the period ending June 30, 2024.

Via The Motley Fool

Topics Earnings

AbCellera Reports Q2 2024 Business Results

August 06, 2024

From AbCellera Biologics Inc.

Via Business Wire

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

July 31, 2024

From AbCellera Biologics Inc.

Via Business Wire

AI-Focused Drug Discovery Stocks Portfolio Up 7% Last Week; Up 19% MTD ↗

July 30, 2024

The AI-powered drug discovery process is expected to grow by a CAGR of 30% by 2030.

Via Talk Markets

"Bubble" In AI/Semiconductor Stocks Began To Re-Inflate On Friday ↗

July 28, 2024

A week ago it was suggested that the AI/semiconductor stocks sector was oversold. The decline bottomed on Wednesday and by the close of business this past Friday the sector had rebounded nicely almost...

Via Talk Markets

Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio? ↗

July 21, 2024

The Baker brothers are billionaires with a successful track record in the biopharmaceutical industry.

Via The Motley Fool

AI-Powered Drug Discovery Stocks Portfolio Up 14% MTD; Still Down 30% YTD ↗

July 18, 2024

To capitalize on the transition to more AI-focused drug development investors need to understand the drug development process and the financial health and market potential of those companies under...

Via Talk Markets

Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD ↗

July 14, 2024

The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average,...

Via Talk Markets

3 Biotech Stocks That Can Gain Exponentially By Leveraging AI ↗

July 02, 2024

Although fraught with risk, these biotech exposures bring enormous upside potential.

Via Talk Markets

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

June 25, 2024

From AbCellera Biologics Inc.

Via Business Wire

Largest Clinical-Stage BioTech Drug Stocks Declined 6% ↗

June 22, 2024

Of the 10 clinical-stage AI-focused and psychedelic compound-based small cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, only 1 advanced this week. On average they...

Via Talk Markets

AI-Focused Drug Discovery Stocks Portfolio Down 4% W/e June 14th ↗

June 17, 2024

The global

Via Talk Markets

Down 57%, Is AbCellera Biologics a Buy on the Dip? ↗

June 13, 2024

Wall Street analysts say this drug developer can more than double your money.

Via The Motley Fool

AI-Focused Drug Discovery Stocks Portfolio Down 2% In May; Up 4% Last Week ↗

June 10, 2024

The global

Via Talk Markets

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

May 28, 2024

From AbCellera Biologics Inc.

Via Business Wire

Largest Clinical-Stage BioTech Drug Stocks Declined Slightly Last Week ↗

May 27, 2024

This article highlights the performances last week and MTD of the 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies along with their areas of focus in our...

Via Talk Markets

A $50B AI Drug Discovery Revolution Has Begun - Here Are 6 Stocks To Consider Investing In ↗

May 20, 2024

The drug development process is very expensive and time-consuming which creates a huge shortage in drug candidates and programs but the advent of AI can significantly shorten and cheapen this process...

Via Talk Markets

Topics Artificial Intelligence

Largest Clinical-Stage BioTech Drug Stocks Declined 3% Last Week ↗

May 13, 2024

Via Talk Markets

3 Stock Gems Hiding in the Nasdaq ↗

May 13, 2024

If you don’t mind taking a risk in the discount section, these undervalued Nasdaq stocks just might surprise some folks.

Via InvestorPlace

5 Of 7 AI Categories Rose, Slightly,Over Past Week ↗

May 11, 2024

The 7 AI categories we track went up marginally (1.0%, on average) the second week of May, after having gone down 0.4% the previous week.

Via Talk Markets

Topics Artificial Intelligence

AbCellera Biologics (ABCL) Q1 2024 Earnings Call Transcript ↗

May 08, 2024

ABCL earnings call for the period ending March 31, 2024.

Via The Motley Fool

Topics Earnings

ABCL Stock Earnings: AbCellera Biologics Beats EPS, Misses Revenue for Q1 2024 ↗

May 07, 2024

ABCL stock results show that AbCellera Biologics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

Via InvestorPlace

AbCellera Reports Q1 2024 Business Results

May 07, 2024

From AbCellera Biologics Inc.

Via Business Wire

Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May ↗

May 05, 2024

We look at the performance of 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies during the first week of May and YTD.

Via Talk Markets

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

May 01, 2024

From AbCellera Biologics Inc.

Via Business Wire

Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week ↗

April 23, 2024

A look at the 10 clinical-stage AI-powered and psychedelic compound-based small-cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, their stock performances last week and...

Via Talk Markets

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.